0.6746
price down icon4.23%   -0.0351
 
loading
Lexaria Bioscience Corp stock is traded at $0.6746, with a volume of 345.45K. It is down -4.23% in the last 24 hours and down -35.88% over the past month. Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
See More
Previous Close:
$0.7097
Open:
$0.7146
24h Volume:
345.45K
Relative Volume:
0.55
Market Cap:
$16.82M
Revenue:
$411.00K
Net Income/Loss:
$-4.85M
P/E Ratio:
-1.5332
EPS:
-0.44
Net Cash Flow:
$-4.88M
1W Performance:
+24.99%
1M Performance:
-35.88%
6M Performance:
-24.48%
1Y Performance:
-68.82%
1-Day Range:
Value
$0.6543
$0.7146
1-Week Range:
Value
$0.515
$0.7197
52-Week Range:
Value
$0.46
$2.38

Lexaria Bioscience Corp Stock (LEXX) Company Profile

Name
Name
Lexaria Bioscience Corp
Name
Phone
250-765-6424
Name
Address
100 - 740 MCCURDY ROAD, KELOWNA
Name
Employee
7
Name
Twitter
Name
Next Earnings Date
2025-07-28
Name
Latest SEC Filings
Name
LEXX's Discussions on Twitter

Compare LEXX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
LEXX
Lexaria Bioscience Corp
0.6758 17.66M 411.00K -4.85M -4.88M -0.44
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
467.85 113.87B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
773.83 80.22B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
405.59 52.56B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ARGX
Argen X Se Adr
802.32 49.31B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
174.74 37.37B 447.02M -1.18B -906.14M -6.1812

Lexaria Bioscience Corp Stock (LEXX) Latest News

pulisher
Jan 02, 2026

Growth Value: Is Lexaria Bioscience Corp Equity Warrant stock dividend yield sustainable2025 Key Lessons & Technical Pattern Based Buy Signals - moha.gov.vn

Jan 02, 2026
pulisher
Jan 02, 2026

Lexaria Bioscience (LEXX) Expected to Announce Earnings on Friday - Defense World

Jan 02, 2026
pulisher
Jan 01, 2026

Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4 - New Castle News

Jan 01, 2026
pulisher
Dec 31, 2025

Lexaria releases additional results from Phase 1b study GLP-1-H24-4 - Yahoo Finance

Dec 31, 2025
pulisher
Dec 30, 2025

Lexaria’s Phase 1b GLP-1 Study Shows Comparable Metabolic Outcomes and Encouraging Blood Pressure Data for DehydraTECH Platform - TipRanks

Dec 30, 2025
pulisher
Dec 30, 2025

Lexaria Bioscience (LEXX) Reports Promising Results from Phase 1 - GuruFocus

Dec 30, 2025
pulisher
Dec 30, 2025

Drug trial in overweight patients ties CBD formula to lower blood pressure - Stock Titan

Dec 30, 2025
pulisher
Dec 30, 2025

Lexaria Bioscience (NASDAQ:LEXX) Shares Up 5.5% – Here’s What Happened - Defense World

Dec 30, 2025
pulisher
Dec 28, 2025

Sentiment Review: Is Lexaria Bioscience Corp Equity Warrant stock dividend yield sustainableMarket Performance Report & Stepwise Trade Execution Plans - moha.gov.vn

Dec 28, 2025
pulisher
Dec 27, 2025

How geopolitical tensions affect Lexaria Bioscience Corp stock2025 Market Sentiment & Verified Entry Point Signals - moha.gov.vn

Dec 27, 2025
pulisher
Dec 27, 2025

Lexaria Bioscience secures $3.5 million in direct offering to boost R&D - MSN

Dec 27, 2025
pulisher
Dec 26, 2025

Capital One Financial To Rally More Than 24%? Here Are Top Analyst Forecasts For Friday - Benzinga

Dec 26, 2025
pulisher
Dec 26, 2025

Lexaria Bioscience stock soars after ending $5M stock sale agreement with JonesTrading - MSN

Dec 26, 2025
pulisher
Dec 26, 2025

Lexaria Bioscience stock price target cut to $1.50 from $4 at H.C. Wainwright By Investing.com - Investing.com South Africa

Dec 26, 2025
pulisher
Dec 26, 2025

Lexaria Bioscience stock price target cut to $1.50 from $4 at H.C. Wainwright - Investing.com

Dec 26, 2025
pulisher
Dec 26, 2025

LEXX: HC Wainwright & Co. Lowers Price Target to $1.50, Maintains Buy Rating | LEXX Stock News - GuruFocus

Dec 26, 2025
pulisher
Dec 24, 2025

LEXX: DehydraTECH Formulation Reduces GLP-1 Agonist Side Effects - Research Tree

Dec 24, 2025
pulisher
Dec 24, 2025

Primary Endpoint Successfully Achieved in Lexaria’s Phase 1b Study GLP-1-H24-4 - York Dispatch

Dec 24, 2025
pulisher
Dec 23, 2025

Lexaria’s DehydraTECH-semaglutide cuts GLP-1 side effects in phase 1b trial and extends cash runway into 2026 - MSN

Dec 23, 2025
pulisher
Dec 23, 2025

Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50% Versus Novo Nordisk's Rybelsus - Benzinga

Dec 23, 2025
pulisher
Dec 23, 2025

Lexaria’s DehydraTECH-Semaglutide Cuts GLP-1 Side Effects in Phase 1b Trial and Extends Cash Runway Into 2026 - TipRanks

Dec 23, 2025
pulisher
Dec 23, 2025

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4 - Investing News Network

Dec 23, 2025
pulisher
Dec 23, 2025

Experimental oral GLP-1 pill cuts side effects by nearly half in trial - Stock Titan

Dec 23, 2025
pulisher
Dec 21, 2025

Is Lexaria Bioscience Corp. stock resilient to inflationJuly 2025 Market Mood & Weekly Consistent Profit Watchlists - Улправда

Dec 21, 2025
pulisher
Dec 20, 2025

What momentum indicators show for Lexaria Bioscience Corp. stockPortfolio Growth Summary & AI Powered Market Trend Analysis - Улправда

Dec 20, 2025
pulisher
Dec 20, 2025

Will Lexaria Bioscience Corp. stock deliver better than expected guidanceQuarterly Profit Review & Safe Capital Investment Plans - Улправда

Dec 20, 2025
pulisher
Dec 20, 2025

Is Lexaria Bioscience Corp. stock a buy on dipsJuly 2025 Technicals & AI Optimized Trading Strategy Guides - Улправда

Dec 20, 2025
pulisher
Dec 20, 2025

Portfolio Recap: What valuation multiples suggest for Lexaria Bioscience Corp. Equity Warrant stockBreakout Watch & Fast Entry and Exit Trade Plans - Улправда

Dec 20, 2025
pulisher
Dec 19, 2025

Setup Watch: Is Lexaria Bioscience Corp. stock resilient to inflationSell Signal & Consistent Profit Trade Alerts - Улправда

Dec 19, 2025
pulisher
Dec 19, 2025

How geopolitical tensions affect Lexaria Bioscience Corp. stockJuly 2025 Short Interest & Free Expert Verified Stock Movement Alerts - DonanımHaber

Dec 19, 2025
pulisher
Dec 19, 2025

Will Lexaria Bioscience Corp. Equity Warrant stock benefit from AI adoptionWeekly Profit Summary & Risk Managed Trade Strategies - DonanımHaber

Dec 19, 2025
pulisher
Dec 19, 2025

Published on: 2025-12-19 15:15:39 - DonanımHaber

Dec 19, 2025
pulisher
Dec 19, 2025

Published on: 2025-12-19 14:32:21 - DonanımHaber

Dec 19, 2025
pulisher
Dec 19, 2025

Is Lexaria Bioscience Corp. Equity Warrant stock trading at a premium valuationWeekly Earnings Recap & Weekly Top Stock Performers List - Улправда

Dec 19, 2025
pulisher
Dec 18, 2025

Momentum Shift: Is Lexaria Bioscience Corp. Equity Warrant stock trading at a premium valuationJuly 2025 Breakouts & Daily Risk Controlled Trade Plans - Улправда

Dec 18, 2025
pulisher
Dec 18, 2025

Lexaria Bioscience Corp (LEXX) is a good investment, but the stock may be undervalued - uspostnews.com

Dec 18, 2025
pulisher
Dec 16, 2025

Lexaria Bioscience Corp. (LEXX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Dec 16, 2025
pulisher
Dec 16, 2025

Lexaria Bioscience Secures $3.5 Million in Capital Through Registered Direct Offering - citybuzz -

Dec 16, 2025
pulisher
Dec 16, 2025

Lexaria Bioscience closes $3.5 million registered direct offering - Investing.com

Dec 16, 2025
pulisher
Dec 16, 2025

Lexaria Bioscience closes $3.5 million registered direct offering By Investing.com - Investing.com Canada

Dec 16, 2025
pulisher
Dec 16, 2025

Lexaria Bioscience (NASDAQ: LEXX) details approximately $3.5 million financing terms - Stock Titan

Dec 16, 2025
pulisher
Dec 16, 2025

Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Bluefield Daily Telegraph

Dec 16, 2025

Lexaria Bioscience Corp Stock (LEXX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Lexaria Bioscience Corp Stock (LEXX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
BUNKA CHRISTOPHER
Director
Jul 30 '25
Buy
0.91
11,900
10,866
281,912
McKechnie William Edward
Director
Jul 29 '25
Buy
0.91
5,000
4,532
18,191
DOCHERTY JOHN MARTIN
President & CSO
Jul 29 '25
Buy
0.93
5,376
4,989
5,376
Carle Vanessa
Secretary
Jul 29 '25
Buy
0.91
750
682
750
CHRISTOPHER RICHARD
Chief Executive Officer
Jul 29 '25
Buy
0.91
15,000
13,641
65,000
$40.59
price up icon 2.45%
$33.12
price up icon 4.10%
$107.28
price up icon 5.34%
$98.35
price up icon 1.49%
biotechnology ONC
$320.86
price up icon 0.11%
$174.46
price down icon 0.43%
Cap:     |  Volume (24h):